Weekly Funding Opportunities

[Med Research]

REMINDER TO ALL RESEARCHERS:  If you are interested to respond to any funding opportunity (internal or external), please notify Med-RA at research at med.fsu.edu<mailto:research at med.fsu.edu>.

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 / R01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://fsucomgrants.wordpress.com/2020/05/01/emergency-awards-rapid-investigation-of-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-and-coronavirus-disease-2019-covid-19-r21-r01-clinical-trial-not-allowed/__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c1HLBwAa4$ >
R21<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-177.html__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c10nuvtcE$ >
R01<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-178.html__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c1uBL8bF4$ >
The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).
Proposals accepted and reviewed (expedited) on a rolling basis. Expires April 30, 2021. Med-RA deadline to receive draft documents: Ten business days before application submission.

Lung Cancer Research Foundation: Disparities in Lung Cancer<https://urldefense.com/v3/__https://www.lungcancerresearchfoundation.org/wp-content/uploads/Request-for-Proposals-2020-Research-Grant-on-Disparities-in-Lung-Cancer-REVISED.pdf__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c1ZNLob90$ >
The foundation invites proposals to advance research dedicated to overcoming disparities in lung cancer. Grants of up to $150,000 over two years will be awarded in support of research dedicated to a wide variety of disparities-related topics, including but not limited to the following: gender disparities in lung cancer burden; causes and risk factors for lung cancer among never-smokers; influence of social and biological risk factors on lung cancer outcomes, access to and use of care, and quality of care; genetic and gene-environment interactions; interactions and contributions of multiple factors (e.g., smoking, genetics, environment, societal factors) to disparities in lung cancer outcomes; contribution of healthcare access and quality to disparities in outcomes; and disparities related to other factors such as geography, socioeconomic status, and age.
Due May 29, 2020. Med-RA deadline to receive draft documents: May 18.

American Heart Association and Enduring Hearts Research Awards in Pediatric Heart Transplantation<https://urldefense.com/v3/__https://professional.heart.org/professional/ResearchPrograms/UCM_505458_AHAEnduring-Hearts-Research-Awards-in-Pediatric-Heart-Transplantation.jsp__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c14nJgCM8$ >
These awards provide support for investigators who are actively conducting research directly related to improving the life expectancy and quality of life of Pediatric Heart Transplant Recipients. This funding opportunity will further these areas of focus by offering competitive research grants in basic, clinical, population, and/or translational research via Collaborative Sciences Awards.
Research Priorities

  *   evidence-based strategies for improving treatment adherence;
  *   early and accurate identification of acute cellular and antibody-mediated rejection and cardiac allograft vasculopathy, including the development of accurate non-invasive methods and strategies for surveillance;
  *   studies on the causes, prevention, and treatment of cardiac allograft vasculopathy;
  *   strategies to improve the viability of donor hearts,
  *   the development of novel immunotherapies by the identification of novel targets, by improving the side-effect profiles of immunotherapies, and/or by improving methods for monitoring the level of immunosuppression.
Applications for the development of new technologies that would address any of these priority areas will also be considered.
Additional consideration will be given to applications that include clinical research or applications that include feasible clinical translations(s).
Letter of intent due June 1, 2020. Med-RA deadline to receive draft documents: May 18.

Congressionally Directed Medical Research Programs
Multiple Sclerosis Research Program<https://urldefense.com/v3/__https://cdmrp.army.mil/funding/msrp__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c1Sj0_WeA$ >
Clinical Trial Award
Pre-application (preproposl): June 17, 2020. Invited full application: October 1, 2020.
Exploration - Hypothesis Development Award
Pre-application (preproposl): June 17, 2020. Invited full application: October 1, 2020.
Investigator Initiated Research Award
Pre-application (preproposl): June 17, 2020. Invited full application: October 1, 2020.
Med-RA deadline to receive preproposal draft documents: June 4.
Breast Cancer Research Program<https://urldefense.com/v3/__https://cdmrp.army.mil/funding/bcrp__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c1PLgPJ0k$ >
Breakthrough Award Levels 1 and 2
Pre-application (letter of intent): September 8, 2020. Application: September 22, 2020.
Med-RA deadline to receive letter of intent draft documents: August 25.
Breakthrough Award Level 3
Pre-application (preproposal): June 24, 2020. Invited full application: October 6, 2020.
Breakthrough Award Level 4
Pre-application (preproposal): June 24, 2020. Invited full application: October 6, 2020.
Med-RA deadline to receive preproposal draft documents: June 11.
Era of Hope Scholar Award
Pre-application (letter of intent): September 8, 2020. Application: September 22, 2020. Confidential letters of recommendation September 25, 2020.
Med-RA deadline to receive letter of intent draft documents: August 25.
Innovator Award
Pre-application (preproposal): June 24, 2020. Invited full application: October 6, 2020. Confidential letters of recommendation October 8, 2020.
Transformative Breast Cancer Consortium Award
Pre-application (preproposal): June 24, 2020. Invited full application: October 6, 2020.
Med-RA deadline to receive preproposal draft documents: June 11.

HRSA Rural Residency Planning and Development Program<https://urldefense.com/v3/__https://www.hrsa.gov/grants/find-funding/hrsa-20-107__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c1CnepHt0$ >
The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year (FY) 2020 Rural Residency Planning and Development (RRPD) Program. The purpose of this program is to develop newly accredited and sustainable rural residency programs in family medicine, internal medicine, public health and general preventive medicine, psychiatry, general surgery, and obstetrics and gynecology, to support expansion of the physician workforce in rural communities. Rural residency programs are accredited medical residency training programs that primarily train residents in rural training sites for greater than 50 percent of their total time in residency, and focus on producing physicians who will practice in rural communities. One common model is the 1+2 Rural Training Track (RTT), where the first year of training occurs within a larger program, typically in an urban hospital or academic medical center, and the final two years in a rural health facility. The new rural residency programs will: (1) achieve accreditation through the Accreditation Council for Graduate Medical Education (ACGME), (2) ensure sustainability through public or private funding beyond the RRPD period of performance, and (3) track residents’ career outcomes post-graduation, including but not limited to retention in rural communities. Funds will support planning and development costs accrued while achieving program accreditation. Hospitals, medical schools and community-based ambulatory settings that have a rural designation along with consortia of urban and rural partnerships are eligible to apply for a grant award.
Due June 30, 2020. Med-RA deadline to receive draft documents: June 17.

Superfund Research Program Occupational Health and Safety Education Programs on Emerging Technologies (R25 – Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-20-011.html__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c1uSZ3QOA$ >
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:

  *   Courses for Skills Development

  *   Research Experiences

  *   Curriculum or Methods Development
The intent of this announcement is to provide an opportunity to Institutions of Higher Education to develop and offer continuing education courses, research experiences, and academic curricula on occupational health and safety management and laboratory practices in the areas of emerging technologies, emerging contaminants, and/or disaster response. Target participants include industrial hygienists, graduate students, postdoctorates, and professionals involved in the research, evaluation, management, and handling of hazardous substances. The Superfund Research Program also expects that such programs will provide a unique educational opportunity to those professionals involved in the training of other personnel for careers in these new industries. These programs are also meant to expand and complement existing educational programs in occupational health and safety and industrial hygiene.
Due August 3, 2020. Med-RA deadline to receive draft documents: July 21.

Arena Pharmaceuticals: Arena of Care Award in IBD<https://urldefense.com/v3/__https://grantsandgiving-arenapharm.steeprockinc.com/arenaofcare.html__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c1q4AAWS4$ >
In an effort to broaden its impact and improve the quality of life for patients with Inflammatory Bowel Disease (IBD), Arena Pharmaceuticals has introduced the Arena of Care Award in IBD, a competitive grant program to support the development and implementation of innovative community-based services and initiatives that address unmet need(s) of those impacted by IBD. Successful proposals for the Arena of Care Award will meet one or more of the following key objectives: increase capacity for innovative programs that address unmet need(s) of the IBD community; increase understanding of IBD through education that shifts perspectives and perceptions to reduce misconceptions and stigma associated with the disease; increase opportunities for IBD stakeholder (e.g., patients, parents/guardians, caregivers) engagement in the development and delivery of IBD education, awareness, and support services; increase health care and service provider awareness of IBD through targeted education and/or training (e.g., IBD information dissemination at primary and specialty HCP offices, outpatient clinics, hospitals, and other community points of care); and reduce disparities in access to IBD health care and support services among patients of diverse ethnic and racial backgrounds, and among other traditionally underserved patient. The annual maximum award amount for an individual organization is $25,000 and $50,000 for collaborative proposals involving two or more organizations).
Due August 31, 2020. Med-RA deadline to receive draft documents: August 18.

Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-180.html__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c11M_aQOk$ >
This Funding Opportunity Announcement (FOA) invites applications that seek to support the identification of shared mechanisms and development of innovative interventions to address multimorbidity or multiple chronic conditions (MCCs) and its consequences. Intervention research supported by this initiative should be designed to study: (1) mechanisms or pathways that prevent MCCs, including the identification of early biomarkers, behavioral pathways, and individual and contextual risk factors and interactions that contribute to the development of common MCCs; (2) targeted therapies and management, including self-management, of MCCs to delay progression and prevent onset of new diseases; and (3) innovative health care partnership models for managing or treating MCCs. Studies may include shared mechanisms, and assessments of interactions between risk factors and interventions that address MCCs at different periods of the lifespan in diverse populations. Use of innovative technologies to assess and intervene on risk factors and pathways are encouraged. Studies may also include those that make use of existing data and/or data linkages to explore new research questions that may be helpful in understanding the impact of mechanisms in isolation or in combination. Of particular interest are interventions that target prevention and treatment of multiple chronic health conditions, including study designs that address therapeutic targets for preventing co-occurring MCCs.
Standard dates apply. First standard due date is October 5, 2020. Expires September 8, 2023. Med-RA deadline to receive draft documents for October 5 standard date: September 22.

Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-179.html__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c1o1uZ3ss$ >
This Funding Opportunity Announcement (FOA) invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinality and life course diversity of multimorbidity. This includes but is not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways using animal models of MCCs, and identification and initial biological, analytical, and clinical evaluation of MCC shared signatures. Also sought are patient-focused studies that capture patient reports and related constructs such as functional limitations and quality of life; analytic approaches best suited for use with multimorbidity data and matched to target populations; and approaches that fully harness the wealth of multimorbidity data available in EHR systems. Studies may make use of existing data and data linkages to explore new research questions related to co-occurring MCCs.
Standard dates apply. First standard due date is October 5, 2020. Expires September 8, 2023. Med-RA deadline to receive draft documents for October 5 standard date: September 22.

Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-027.html__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c1ppEZhF0$ >
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from institutions/organizations to participate in a cooperative research group, the Mucosal Immunology Studies Team (MIST), focusing on immune mechanisms and immune regulation at mucosal surfaces of the respiratory, gastrointestinal and urogenital tracts. The main objective of this program is to break new ground in the understanding of basic mucosal immune mechanisms by introducing new ideas, approaches and technologies that address the difficult questions in mucosal immunology.
Due October 9, 2020. Med-RA deadline to receive draft documents: September 28.

U.S. – India Collaborative Environmental Health Research Program (R01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-20-010.html__;!!PhOWcWs!kf2iEIcVa0m909FiaIWgmrkeYzJPabhs2pHFtX3b9t1xxXywRA-g6-Dx8LsIJQYfrKZGTFqp06c1Tg1hLEA$ >
The purpose of the United States (U.S.)-India Program for Environmental Health Collaborative Research is to stimulate and promote collaborative basic, translational, and clinical research between U.S.-based researchers and Indian researchers and to gain a comprehensive understanding of the impacts of environmental insults on children and adults across all organ systems (e.g. pulmonary, cardiovascular, cancer, and neurological disorders). The National Institute of Environmental Health Sciences (NIEHS) and the Indian Council for Medical Research (ICMR) are interested in supporting collaborative research and research training through joint U.S.-India partnerships that address or seek to understand how exposures to toxic environmental insults alter biologic processes and are linked to disease initiation, progression, or morbidity. In addition, both agencies are interested in research that leads to the development of prevention and intervention strategies to reduce environmentally induced diseases. To promote these collaborative efforts from the outset, the partnering U.S. and Indian investigators must work jointly to submit identical applications to NIH and the Indian Council of Medical Research (ICMR), respectively.
Due October 15, 2020. Med-RA deadline to receive draft documents: October 5.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20200501/f2111db2/attachment.html>